Related Experiment Video
Updated: Jan 20, 2026
Culturing Microglia from the Neonatal and Adult Central Nervous System
Published on: August 9, 2013
Medulloblastoma and central nervous system germ cell tumors in adults: is pediatric experience applicable?
Maurizio Mascarin1, Elisa Coassin1, Enrico Franceschi2
1SOSD Oncologia Integrata del Giovane e Radioterapia Pediatrica, Centro di Riferimento Oncologico (CRO) IRCCS, Aviano, Italy.
Abstract:
Medulloblastoma and central nervous system (CNS) germ cell tumors are very rare in adults, while they account for 25% and 5% of brain tumors in children, respectively (Pastore et al. Eur J Cancer 42:2064-208, 2006). Pediatric experiences, mostly from randomized and controlled clinical trials, have led to different tailored treatments, based on various risk factors, including histology, and extent of disease. For medulloblastoma, biological features have recently emerged that enable therapies to be scaled down in some cases, or pursued more aggressively in the event of chromosomal and/or genetic alterations (Massimino et al. Crit Rev Oncol Hematol 105:35-51, 2016). Such refinements are still impossible for adult patients due to the lack of similar clinical trials that might provide the same or a different understanding regarding patients' prognosis, long-term survival, quality of life, and acute and late toxicities. This review aims to contribute to the debate on the treatment of adults with these two diseases and promote the creation of broad-based, national and international trials to advance our knowledge in this area and to share the skills between pediatric and adult oncologists as adolescent and young adults (AYA) brain tumor national boards are currently requiring.
Insights
Adults with rare brain tumors like medulloblastoma and CNS germ cell tumors lack tailored treatments due to insufficient clinical trials. This review advocates for collaborative research to improve adult patient outcomes and care.
Area of Science:
- Neuro-oncology
- Pediatric Oncology
- Adult Oncology
Background:
- Medulloblastoma and CNS germ cell tumors are rare in adults but common in children.
- Pediatric treatment protocols are informed by extensive clinical trials and risk stratification.
- Adult treatment strategies lag due to a lack of similar research, impacting prognosis and toxicity understanding.
Purpose of the Study:
- To review current treatment approaches for adult medulloblastoma and CNS germ cell tumors.
- To highlight the disparities in research between pediatric and adult neuro-oncology.
- To advocate for the development of collaborative, international clinical trials for adult patients.
Main Methods:
- Literature review of existing studies on medulloblastoma and CNS germ cell tumors in adults and children.
- Analysis of treatment refinements in pediatric populations based on histology and biological features.
- Identification of knowledge gaps in adult patient prognosis, survival, and toxicity.
Main Results:
- Pediatric brain tumor research has led to tailored treatments, including risk-adapted therapies for medulloblastoma based on molecular features.
- Adult patients with these rare tumors do not benefit from similar evidence-based treatment refinements.
- Significant gaps exist in understanding adult patient outcomes, long-term survival, and treatment toxicities.
Conclusions:
- There is a critical need for dedicated clinical trials in adult medulloblastoma and CNS germ cell tumors.
- Collaboration between pediatric and adult oncologists is essential to advance care for adolescent and young adult (AYA) patients.
- Developing broad-based national and international trials will improve knowledge sharing and treatment efficacy.
Related Concept Videos
01:25What is a Nervous System?
01:14The Parasympathetic Nervous System
01:25The Sympathetic Nervous System
01:33Adult Stem Cells
01:25The Central Dogma
01:31Nervous Tissue: Glial Cells
The CNS glial cell includes the astrocytes, the oligodendrocytes, the microglia, and the ependymal cells.
Astrocytes are star-shaped glial...